Nautilus Biotechnology (NASDAQ:NAUT) Shares Up 5.6%

Nautilus Biotechnology, Inc. (NASDAQ:NAUT – Get Rating) shot up 5.6% during mid-day trading on Monday . The company traded as high as $2.45 and last traded at $2.44. 62,672 shares changed hands during mid-day trading, a decline of 42% from the average session volume of 107,658 shares. The stock had previously closed at $2.31.

Nautilus Biotechnology Price Performance

The stock’s fifty day simple moving average is $2.52 and its 200-day simple moving average is $2.13. The firm has a market cap of $304.68 million, a PE ratio of -5.30 and a beta of 0.96.

Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) last released its quarterly earnings data on Tuesday, May 2nd. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.04. Analysts expect that Nautilus Biotechnology, Inc. will post -0.7 earnings per share for the current year.

Institutional Trading of Nautilus Biotechnology

Hedge funds and other institutional investors have recently made changes to their positions in the business. UBS Group AG acquired a new stake in shares of Nautilus Biotechnology in the fourth quarter valued at about $26,000. Shay Capital LLC purchased a new stake in shares of Nautilus Biotechnology in the 4th quarter valued at approximately $30,000. Mariner LLC purchased a new position in shares of Nautilus Biotechnology in the 4th quarter valued at $32,000. Prelude Capital Management LLC purchased a new position in shares of Nautilus Biotechnology in the 3rd quarter valued at $37,000. Finally, Citigroup Inc. boosted its stake in Nautilus Biotechnology by 130.3% during the 1st quarter. Citigroup Inc. now owns 10,387 shares of the company’s stock worth $45,000 after purchasing an additional 5,877 shares during the period. Institutional investors and hedge funds own 45.25% of the company’s stock.

About Nautilus Biotechnology

(Get Rating)

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.